Ginkgo Bioworks Holdings (DNABW) Tax Provisions (2020 - 2026)
Ginkgo Bioworks Holdings (DNABW) reported Tax Provisions of -$80000.0 for Q1 2026, down 190.91% on a YoY basis from $88000.0 in Q1 2025, and up 87.56% quarter-over-quarter from -$643000.0 in Q4 2025.
Ginkgo Bioworks Holdings (DNABW) Tax Provisions (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings has reported Tax Provisions for 7 years, with the latest figure at -$80000.0 in Q1 2026.
- For the quarter ending Q1 2026, Tax Provisions fell 190.91% year-over-year to -$80000.0; the trailing twelve-month figure through Mar 2026 stood at -$1.0 million (down 138.15% YoY), and the FY2025 full-year result was -$837000.0, down 74.74% from the prior year.
- Tax Provisions for Q1 2026 stood at -$80000.0, up from -$643000.0 in the prior quarter.
- The five-year high for Tax Provisions was $190000.0 in Q2 2024, with the low at -$14.8 million in Q4 2022.
- Historically, Tax Provisions has averaged -$970235.3 across 5 years, with a median of -$45000.0 in 2022.
- Annual changes were most pronounced in 2022 — Tax Provisions tumbled 2062.52% — and 2023, when it soared 248.89%.
- Ginkgo Bioworks Holdings' Tax Provisions stood at -$14.8 million in 2022, then surged by 98.66% to -$198000.0 in 2023, then tumbled by 64.14% to -$325000.0 in 2024, then slumped by 97.85% to -$643000.0 in 2025, then surged by 87.56% to -$80000.0 in 2026.
- The last three Tax Provisions figures came in at -$80000.0 (Q1 2026), -$643000.0 (Q4 2025), and $1000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -11.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 216,000.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -859,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 221.50 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ginkgo Bioworks Holdings | - | - | 16.38 Mn | -80,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -80,000.00 |
| Dec 31, 2025 | -643,000.00 |
| Sep 30, 2025 | 1,000.00 |
| Jun 30, 2025 | -283,000.00 |
| Mar 31, 2025 | 88,000.00 |
| Dec 31, 2024 | -325,000.00 |
| Sep 30, 2024 | -375,000.00 |
| Jun 30, 2024 | 190,000.00 |
| Mar 31, 2024 | 31,000.00 |
| Dec 31, 2023 | -198,000.00 |
| Sep 30, 2023 | -22,000.00 |
| Jun 30, 2023 | 67,000.00 |
| Mar 31, 2023 | 82,000.00 |
| Dec 31, 2022 | -14.77 Mn |
| Sep 30, 2022 | -28,000.00 |
| Jun 30, 2022 | -45,000.00 |
| Mar 31, 2022 | -184,000.00 |
| Dec 31, 2021 | -683,000.00 |
| Sep 30, 2021 | -207,000.00 |
| Jun 30, 2021 | -431,000.00 |